Jensen Margaret E Valeur Net Worth

The estimated Net Worth of Jensen Margaret E Valeur is at least $2.05 Milion dollars as of 2 November 2015. Jensen Valeur owns over 50,000 units of Retrophin stock worth over $3,500 and over the last 22 years Jensen sold RTRX stock worth over $2,046,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jensen Valeur RTRX stock SEC Form 4 insiders trading

Jensen has made over 2 trades of the Retrophin stock since 2015, according to the Form 4 filled with the SEC. Most recently Jensen sold 50,000 units of RTRX stock worth $1,023,000 on 2 November 2015.

The largest trade Jensen's ever made was selling 50,000 units of Retrophin stock on 2 November 2015 worth over $1,023,000. On average, Jensen trades about 4,167 units every 0 days since 2003. As of 2 November 2015 Jensen still owns at least 50,000 units of Retrophin stock.

You can see the complete history of Jensen Valeur stock trades at the bottom of the page.

What's Jensen Valeur's mailing address?

Jensen's mailing address filed with the SEC is C/O RETROPHIN, INC., 777 THIRD AVENUE, 22ND FL., NEW YORK, NY, 10017.

Insiders trading at Retrophin

Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer a Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.

What does Retrophin do?

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Complete history of Jensen Valeur stock trades at Neurocrine Biosciences a Retrophin

Retrophin executives and stock owners

Retrophin executives and other stock owners filed with the SEC include:

• Eric Dube,
  President, Chief Executive Officer, Director
• Elizabeth Reed,
  Senior Vice President, General Counsel and Corporate Secretary
• Noah Rosenberg,
  Chief Medical Officer
• Peter Heerma,
  Chief Commercial Officer
• William Rote,
  Senior Vice President and Head of Research and Development
• Laura Clague,
  Chief Financial Officer, Senior Vice President
• Stephen Aselage,
  Director
• Sandra Poole,
  Independent Director
• Gary Lyons,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• Jeffrey Meckler,
  Independent Director
• John Orwin,
  Independent Director
• Roy Baynes,
  Independent Director
• Ron Squarer,
  Independent Director
• Suzanne Bruhn,
  Independent Director
• Neil F. Mc Farlane,
  Chief Operating Officer
• Jensen Margaret E Valeur,
  General Counsel
• John W Kozarich,
  Director
• Alvin Shih,
  EVP of Research & Development
• Cornelius E Golding,
  Director
• Steve Aselage,
  Director
• Martin Shkreli,
  Chief Executive Officer
• Steven Gary Richardson,
  Director
• Horacio Plotkin,
  Chief Medical Officer
• Jeffrey Paley,
  Director
• Marc L Panoff,
  Chief Financial Officer